21 results about "Dinitrophenyl" patented technology

The invention relates to the technical field of preparation of N-(2, 4-dinitrophenyl)-4-nitrobenzoyl aniline, in particular to a method for preparing a nitro amide compound by adopting a microreactor. The method for preparing the nitro amide compound comprises the following steps: introducing a sulfuric acid solution of 4-nitro-N-phenylbenzamide and a nitric acid aqueous solution into a microreactor, and reacting to obtain N-(2, 4-dinitrophenyl)-4-nitrobenzamide; the microreactor is provided with at least two reaction modules which are connected in series, and a sulfuric acid solution of 4-nitro-N-phenylbenzamide is divided into at least two strands which are respectively fed into a first reaction module of the microreactor and other reaction modules except the first reaction module; and the nitric acid aqueous solution enters the microreactor in a way of at least one stream. According to the method, the microreactor is used as a reaction carrier, the temperature in the reaction process is controllable, the raw material conversion rate is increased, and the residual amount of an intermediate N-4-nitro-(4-nitrophenyl) benzamide is reduced.

The invention relates to a fluorescent probe based on a benzothiazole structure as well as a preparation method and application of the fluorescent probe, and belongs to the technical field of biochemistry. The structural formula of the fluorescent probe based on the benzothiazole structure is shown in the specification, a benzothiazole group with an ESIPT light-emitting mechanism is selected as a fluorophore, 2, 4 dinitrophenyl (DNP) is selected as a blocking group of ESIPT and an H2S recognition group, and a pyrimidine group is introduced to synthesize the hydrogen sulfide fluorescent probe. The fluorescent probe provided by the invention has large Stokes displacement, high sensitivity, good selectivity and stability and remarkable fluorescence opening response characteristics, and is suitable for visualizing exogenous and endogenous H2S in living cells, the preparation method of the test strip loaded with the probe is simple, and H2S generated in a food deterioration process can be rapidly and conveniently detected. # imgabs0 #

[Problem] To provide a method for fluorescent labeling of an intracellular protein using fluorescence ON / OFF control technology which can be applied to various cells. [Solution] A method for fluorescent labeling of an intracellular protein that includes fluorescent labeling of the target protein by obtaining, in a cell, a fusion protein of a protein to be labeled and an anti-DNP (dinitrophenyl compound) antibody, bringing a compound represented by formula (I) or a salt thereof into contact with the cell, and reacting the fusion protein with the compound represented by formula (I) or salt thereof. The anti-DNP antibody in the fusion protein is an anti-DNP antibody containing a light chain containing VL-CDR1 comprising an amino acid sequence represented by SEQ ID NO: 1, VL-CDR2 comprising an amino acid sequence represented by SEQ ID NO: 2, and VL-CDR3 comprising an amino acid sequence represented by SEQ ID NO: 3 and a heavy chain containing VH-CDR1 comprising an amino acid sequence represented by SEQ ID NO: 4, VH-CDR2 comprising an amino acid sequence represented by SEQ ID NO: 5, and VH-CDR3 comprising an amino acid sequence represented by SEQ ID NO: 6, or an antigen-binding fragment thereof. The anti-DNP antibody or an antigen-binding fragment thereof is a single-chain Fv (scFv).

The application discloses a kind of 2,4-dinitrophenyl compounds and preparation method thereof, belong to the field of medicinal chemistry.The application provides a kind of 2,4-dinitrophenyl compounds or its pharmaceutically acceptable salt as shown in structure (I), the compound or its pharmaceutically acceptable salt compared to HU6 has more excellent pharmacokinetic characteristics, and can be used as mitochondrial uncoupling agent, and has treatment prospect to obesity, non-alcoholic fatty liver disease, liver steatosis or diabetes.

The present technology relates to the field of drug delivery and provides molecules comprising or consisting of at least one protein-based carrier building block, wherein the protein-based carrier building block comprises at least two attachment point(s) or conjugation site(s), wherein the molecule further comprises (i) at least two antibody-binding components, preferably at least two hapten units, preferably selected from phosphorylcholine, dinitrophenyl (DNP), galactose-α-1,3-galactose (αGal) and rhamnose (Rha), more preferably at least two rhamnose molecules, covalently linked, directly or by means of a linker, to at least one conjugation site or attachment point comprised in the at least one protein-based building block and (ii) at least one targeting moiety covalently linked, directly or by means of a linker, to at least one conjugation site or attachment point comprised in the at least one protein- based building block. In particular, the at least one protein-based building block comprised in the molecule of the technology: a) comprises at least one conjugation site or attachment point; b) has a molecular mass of 2.5 to 70 kDa; c) has a globular three-dimensional (3D) structure; d) has a solubility of 10 mg / mL or more, measured in an aqueous solution at room temperature; and e) does not specifically bind to any human protein or binds one or more human proteins with a KD value greater than 5x10-4 mol / litre.

This invention relates to the field of organic synthesis technology, specifically disclosing a method for preparing N-(2,4-diaminophenyl)-4-aminobenzamide. The method involves using N-(2,4-dinitrophenyl)-4-nitrobenzamide as a raw material, adding a catalyst, buffer salt, and water, mixing the mixture, and then purging with nitrogen gas to maintain pressure. The nitrogen gas is then replaced with hydrogen gas, and a hydrogenation reaction is carried out under a hydrogen atmosphere. After the reaction is complete, an acid is added to quench the reaction, the catalyst is removed by filtration, and then an alkali is added to adjust the pH to above 8. The mixture is then filtered to obtain crude N-(2,4-diaminophenyl)-4-aminobenzamide. The crude product is purified by recrystallization and finally dried to obtain N-(2,4-diaminophenyl)-4-aminobenzamide. The method provided by this invention has high selectivity, few side reactions, protects the amide bond from hydrolysis, and produces a product with high purity.

The present invention provides novel 2, 4-dinitrophenol (DNP) derivatives and prodrugs thereof as modulators of mitochondrial function. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of their use in the treatment of various diseases and conditions associated or associated with mitochondrial dysfunction (e.g., obesity, diabetes, insulin resistance, liver disease, heart failure or renal failure, neurodegenerative disease, or aging-related disease).

The present invention belongs to the field of fluorescent probe technology, specifically a carbazole fluorescent probe for rapid and efficient detection of H2S, its synthesis method, and application. The compound is 9-(4-(2,4-dinitrophenoxy)phenyl)-9H-carbazole, having a structure of formula (1): #imgabs0#. The probe can selectively identify H2S molecules. The fluorescent probe uses a carbazole molecule as a fluorescent group and then links a 2,4-dinitrophenyl group at the position of the hydroxyl group to form a carbazole fluorescent compound. The carbazole fluorescent probe is a fluorescent probe based on a thiolysis reaction. In the presence of H2S, a thiolysis reaction can occur rapidly, removing the 2,4-dinitrophenyl group and emitting strong fluorescence. It can be widely used to detect H2S in cells, soil, and water.

The present technology relates to the field of drug delivery and provides molecules comprising or consisting of at least one protein-based carrier building block, wherein the protein-based carrier building block comprises at least two attachment point(s) or conjugation site(s), wherein the molecule further comprises (i) at least two antibody-binding components, preferably at least two hapten units, preferably selected from phosphorylcholine, dinitrophenyl (DNP), galactose-α-1,3-galactose (αGal) and rhamnose (Rha), more preferably at least two rhamnose molecules, covalently linked, directly or by means of a linker, to at least one conjugation site or attachment point comprised in the at least one protein-based building block and (ii) at least one targeting moiety covalently linked, directly or by means of a linker, to at least one conjugation site or attachment point comprised in the at least one protein- based building block. In particular, the at least one protein-based building block comprised in the molecule of the technology: a) comprises at least one conjugation site or attachment point; b) has a molecular mass of 2.5 to 70 kDa; c) has a globular three-dimensional (3D) structure; d) has a solubility of 10 mg / mL or more, measured in an aqueous solution at room temperature; and e) does not specifically bind to any human protein or binds one or more human proteins with a KD value greater than 5x10-4 mol / litre.

The present technology relates to the field of drug delivery and provides molecules comprising or consisting of at least one protein-based carrier building block, wherein the protein-based carrier building block comprises at least two attachment point(s) or conjugation site(s), wherein the molecule further comprises (i) at least two antibody-binding components, preferably at least two hapten units, preferably selected from phosphorylcholine, dinitrophenyl (DNP), galactose-α-1,3-galactose (αGal) and rhamnose (Rha), more preferably at least two rhamnose molecules, covalently linked, directly or by means of a linker, to at least one conjugation site or attachment point comprised in the at least one protein-based building block and (ii) at least one targeting moiety covalently linked, directly or by means of a linker, to at least one conjugation site or attachment point comprised in the at least one protein-based building block.In particular, the at least one protein-based building block comprised in the molecule of the technology:a) comprises at least one conjugation site or attachment point;b) has a molecular mass of 2.5 to 70 kDa;c) has a globular three-dimensional (3D) structure;d) has a solubility of 10 mg / mL or more, measured in an aqueous solution at room temperature; ande) does not specifically bind to any human protein or binds one or more human proteins with a KD value greater than 5×10−4 mol / litre·ft

This invention relates to the field of N-(2,4-dinitrophenyl)-4-nitrobenzamide preparation technology, specifically to a green method for preparing nitramide compounds. The method involves adding a catalyst and dispersant to a reactor and mixing them uniformly. Then, a first and a second stream of materials are simultaneously added dropwise to the reactor for reaction. The temperature within the system is controlled during the dropwise addition. After the dropwise addition is complete, the temperature is increased to continue the reaction. After the reaction is completed, N-(2,4-dinitrophenyl)-4-nitrobenzamide is obtained through post-treatment. The first stream is a dispersion containing 4-nitro-N-phenylbenzamide, and the second stream is a nitrating agent consisting of a uniform mixture of N₂O₅ and nitric acid. This preparation method features high product conversion rate, a mild reaction process, safe and controllable production process, effectively reduces the amount of residual intermediates, and minimizes pollution.

The invention provides a 2, 4-dinitrophenoxy compound as shown in the following general formula I or a pharmaceutically acceptable salt of the 2, 4-dinitrophenoxy compound. The invention also provides a 2, 4-dinitrophenoxy pharmaceutical composition with mitochondrial uncoupling activity, and the composition comprises a therapeutically effective amount of one or more of the 2, 4-dinitrophenoxy compounds as shown in the general formula I and pharmaceutically acceptable salts thereof as active ingredients, and pharmaceutically acceptable auxiliary materials, the invention also relates to application of the compound as shown in the general formula I or the pharmaceutically acceptable salt thereof as a medicine of a mitochondrial uncoupling agent, in particular to application in preparation of the medicine as the mitochondrial uncoupling agent.

This invention presents a novel near-infrared fluorescent probe, TPA-NI-NO2, prepared using triphenylamine-naphthalimide as the fluorescent group and 2,4-dinitrophenyl ether as the recognition group. This fluorescence-on type probe is used for the detection of 4-methoxythiophenol (MTP) and exhibits good selectivity and anti-interference properties. Under qualitative detection of MTP, bright orange fluorescence with a rapid response is observed. Under quantitative detection, the fluorescence emission intensity at 607 nm after excitation at 470 nm shows a significant linear correlation with the MTP concentration, with a detection limit reaching 80 nM. This probe can also be used for detection at environmental pH values ​​from 2 to 12 and for intracellular detection, showing broad development prospects in environmental and biological sensing applications.

The present technology relates to the field of drug delivery and provides molecules comprising or consisting of at least one protein-based carrier building block, wherein the protein-based carrier building block comprises at least two attachment point(s) or conjugation site(s), wherein the molecule further comprises (i) at least two antibody-binding components, preferably at least two hapten units, preferably selected from phosphorylcholine, dinitrophenyl (DNP), galactose-α-1,3-galactose (αGal) and rhamnose (Rha), more preferably at least two rhamnose molecules, covalently linked, directly or by means of a linker, to at least one conjugation site or attachment point comprised in the at least one protein-based building block and (ii) at least one targeting moiety covalently linked, directly or by means of a linker, to at least one conjugation site or attachment point comprised in the at least one protein- based building block. In particular, the at least one protein-based building block comprised in the molecule of the technology: a) comprises at least one conjugation site or attachment point; b) has a molecular mass of 2.5 to 70 kDa; c) has a globular three-dimensional (3D) structure; d) has a solubility of 10 mg / mL or more, measured in an aqueous solution at room temperature; and e) does not specifically bind to any human protein or binds one or more human proteins with a KD value greater than 5x10-4 mol / litre.

The application belongs to the technical field of fluorescent probes, and particularly relates to a phosphofluorene fluorescent probe for rapidly and efficiently detecting H2S as well as a synthesis method and application thereof. The phosphofluorene fluorescent probe has the structure of formula (1): the probe can selectively recognize H2S molecules, the fluorescent probe takes a phosphofluorene molecule as a fluorescent group, and then links a 2,4-dinitrophenyl ether group at the position of a hydroxyl group to form a phosphofluorene fluorescent compound. The phosphofluorene fluorescent probe is a fluorescent probe based on a sulfurolysis reaction, can rapidly occur the sulfurolysis reaction in the presence of H2S, and can emit strong fluorescence by removing the 2,4-dinitrophenyl ether group. The phosphofluorene fluorescent probe can be widely applied to detection of H2S in cells, soil and water bodies.

The present invention relates to a method for determining the presence of lung cancer in a subject. The method comprises: (i) determining the level of one or more biomarkers in a sample from the subject; and (ii) comparing the level of said one or more biomarkers with the level of said one or more metabolites in a control sample to determine whether lung cancer is present in the subject. The biomarkers are selected from: 2-methoxyestrone 3-sulfate, testosterone glucuronide, androsterone glucuronide, 5a-dihydrotestosterone sulfate, corticrocin, octanoic acid, beta-citryl-L-glutamic acid, 2-hydroxymuconic semialdehyde, 5,6,11-dodecatriynoic acid, creatine riboside, 3-(Carboxymethyl)-3-hydroxypentanedioic acid, adenosine phosphosulfate, 7,8-dihydroneopterin 3'-phosphate, cis,cis,cis-10,13,16-Docosatrienoyl-CoA, inosine, N-(2,4-Dinitrophenyl)-2,4-dinitroaniline, prostaglandin M, pentadecenoic acid, PE(22:0 / P-18:0), carbamoyl phosphate, 2-hydroxy-3-oxohexanedioic acid, galactosylceramide (d18:1 / 22:0) and PE-NMe2(18:1(11Z) / 22:1(13Z)).

This invention discloses a method for synthesizing a class of energetic compounds of 3-(3,5-dinitrophenyl)-1,2,4-oxadiazole. The structural feature of these compounds is a 3-(3,5-dinitrophenyl)-1,2,4-oxadiazole ring as the basic skeleton, with trifluoromethyl, trichloromethyl, amino, methylazido, and methyl hydroxyl groups as substituents. This invention belongs to the field of energetic materials technology. The 5-trifluoromethyl-3-(3,5-dinitrophenyl)-1,2,4-oxadiazole and 5-methylazido-3-(3,5-dinitrophenyl)-1,2,4-oxadiazole described in this invention possess low melting points and low sensitivity, showing promising applications in cast-supported explosives.

A method for determining the presence of lung cancer in a subject comprises: (i) determining the level of one or more biomarkers in a sample from the subject; and (ii) comparing the level of said one or more biomarkers with the level of said one or more metabolites in a control sample to determine whether lung cancer is present in the subject. The biomarkers are selected from: 2-methoxyestrone 3-sulfate, testosterone glucuronide, androsterone glucuronide, 5a-dihydrotestosterone sulfate, corticrocin, octanoic acid, beta-citryl-L-glutamic acid, 2-hydroxymuconic semialdehyde, 5,6,11-dodecatriynoic acid, creatine riboside, 3-(carboxymethyl)-3-hydroxypentanedioic acid, adenosine phosphosulfate, 7,8-dihydroneopterin 3’-phosphate, cis,cis,cis-10,13,16-docosatrienoyl-CoA, inosine, N- (2,4-dinitrophenyl)-2,4-dinitroaniline, prostaglandin M, pentadecenoic acid, PE(22:0 / P-18:0), carbamoyl phosphate, 2-hydroxy-3-oxohexanedioic acid, galactosylceramide (d18:1 / 22:0) and PE-NMe2(18:1(11Z) / 22:1(13Z)). The biomarkers may be detected using mass spectrometry, or by enzyme-linked immunosorbent assay (ELISA). Preferably, the sample is a urine sample.